Showing results (431-440 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|May 16, 2014
Regression analysis of indicating multiple incremental cost-effectiveness ratios for non-small cell lung cancer treatmentNaohiro Nakahara, Isao KamaeJournal of Medical Economics|November 17, 2012
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitorsSaurabh Ray, Vijayveer Bonthapally, Kyle D Holen, et al.Journal of Medical Economics|May 21, 2014
Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependenceEmilie Clay, Amine Khemiri, Vladimir Zah, et al.Journal of Medical Economics|May 17, 2014
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirinT Lanitis, F E Cotté, A F Gaudin, et al.Journal of Medical Economics|June 4, 2014
Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plansRami Ben-Joseph, Chi-Chang Chen, Ajita P De, et al.Journal of Medical Economics|June 14, 2014
Hospital economic impact from hemostatic matrix usage in cardiac surgeryScott M Tackett, Rebecca Sugarman, Huub T C Kreuwel, et al.Journal of Medical Economics|September 8, 2012
Medicare patient experience with vagus nerve stimulation for treatment-resistant depressionRachel L Feldman, David L Dunner, James S Muller, et al.Journal of Medical Economics|September 6, 2012
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programsEdward P Armstrong, Grant H Skrepnek, Medha Sasane, et al.Journal of Medical Economics|August 9, 2012
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysisSonya J Snedecor, John A Carter, Satyin Kaura, et al.Journal of Medical Economics|September 29, 2012
Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analysesH J Henk, L Becker, H Tan, et al.Pageof 241